The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nationwide large-scale investigation of microsatellite instability status in more than 18,000 patients with various advanced solid cancers.
 
Kiwamu Akagi
Research Funding - FALCO biosystems (Inst); FALCO biosystems (Inst); FALCO biosystems (Inst); FALCO biosystems (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst)
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Hiroya Taniguchi
Honoraria - Bayer; Bayer; Bayer; Bayer; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Lilly Japan; Lilly Japan; Lilly Japan; Lilly Japan; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
 
Kaname Nakatani
No Relationships to Disclose
 
Daisuke Aoki
Honoraria - MSD K.K; MSD K.K; MSD K.K; MSD K.K
 
Takeshi Kuwata
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Chugai/Roche; Chugai/Roche; Chugai/Roche; Chugai/Roche; MSD; MSD; MSD; MSD
Research Funding - Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
 
Takayuki Yoshino
Research Funding - Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst); Sumitomo Dainippon (Inst)